Key Takeaways
- Hexarelin binds GHSR-1a (the ghrelin receptor) and CD36; sermorelin binds the GHRH receptor. These are different receptors with different downstream effects and different side-effect profiles.
- Sermorelin was once FDA-approved (as Geref), giving it a regulatory evidence record. Hexarelin has never been approved and has been studied only in small human trials.
- Hexarelin produces meaningfully higher cortisol and prolactin elevation than sermorelin in human studies, a practical concern for longer protocols.
- Both peptides have plasma half-lives measured in minutes and require subcutaneous injection; oral and transdermal administration is not pharmacologically supported.
- Desensitization is a real and documented limitation of hexarelin, appearing within weeks of continuous high-dose use. Sermorelin has a lower desensitization risk in clinical practice.
What is the short answer on hexarelin vs sermorelin?
Hexarelin and sermorelin both stimulate growth hormone release but through entirely different receptors. Sermorelin mimics GHRH and has a cleaner side-effect profile for longer use. Hexarelin is more potent per dose and has unique cardiac receptor activity but causes more cortisol and prolactin elevation and desensitizes faster. Neither is a clear universal winner.Table of Contents
- How does each peptide actually work at the receptor level?
- What is the evidence quality for each peptide?
- Head-to-head comparison table
- Which peptide has worse side effects?
- Does hexarelin really desensitize faster?
- What do most comparison pages get wrong?
- Why short half-life matters and what it means for dosing timing
- How to read a COA and judge product quality
- FAQ
- Sources
How does each peptide actually work at the receptor level?
Sermorelin is a 29-amino-acid synthetic analogue of endogenous growth hormone-releasing hormone (GHRH 1-29). It binds the GHRH receptor (GHRHR), a Gs-protein-coupled receptor expressed on somatotroph cells of the anterior pituitary. Binding activates adenylyl cyclase, raises intracellular cAMP, and triggers GH synthesis and pulsatile release. Because the mechanism depends on intact somatotroph function and natural somatostatin tone, the GH pulse sermorelin produces stays within physiological range. It does not independently affect cortisol, prolactin, or ACTH pathways because GHRHR expression is largely confined to pituitary somatotrophs.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Hexarelin is a synthetic hexapeptide (His-D-2MeTrp-Ala-Trp-D-Phe-Lys-NH2) belonging to the growth hormone-releasing peptide (GHRP) class. It binds two distinct receptors:
- GHSR-1a, the ghrelin receptor, expressed on pituitary somatotrophs and hypothalamic neurons. Activation here stimulates GH release and also suppresses somatostatin, amplifying the GH pulse. GHSR-1a is also expressed in the hypothalamus, adrenal cortex, and corticotrophs, which is why hexarelin raises cortisol and prolactin.
- CD36, a class B scavenger receptor expressed on cardiomyocytes and macrophages. This GH-independent pathway has been associated with cardioprotective and anti-fibrotic effects in animal and in vitro models. Clinical significance in humans has not been established through controlled trials.
The key mechanistic difference is that sermorelin requires the hypothalamic-pituitary axis to be largely intact and does not amplify GH beyond physiological pulsatile norms. Hexarelin can override somatostatin suppression and produce supraphysiological GH peaks at higher doses, but this comes with broader receptor engagement and corresponding side effects.
What is the evidence quality for each peptide?
| Claim | Best evidence type | Direction | Confidence | Key caveat |
|---|---|---|---|---|
| Sermorelin stimulates GH release in adults | Human RCTs, FDA pharmacology review (Geref NDA) | Positive | High | Most data from children or GH-deficient adults; healthy adult wellness data are sparse |
| Hexarelin stimulates GH in healthy adults | Multiple small human trials (e.g., Ghigo et al., JCEM 1994) | Positive | Moderate | Studies are small (commonly under 20 subjects) and short-duration |
| Hexarelin raises cortisol and prolactin | Human pharmacology studies | Positive (adverse effect direction) | Moderate to High | Effect is dose-dependent; magnitude at low research doses is clinically mild in most reports |
| Hexarelin cardioprotective via CD36 | Animal studies, in vitro | Positive in animal models | Very Low (for humans) | No human RCT data; mechanism is real but clinical translation unproven |
| Hexarelin desensitization with continuous dosing | Human pharmacology studies | Positive (confirmed) | Moderate | Magnitude and timeline vary by dose and individual GHSR-1a density |
| Sermorelin improves body composition or sleep in aging adults | Small human trials and case series | Weakly positive | Low | Confounded by variable GH secretory reserve; no large RCTs in this population |
| Sermorelin has lower desensitization risk than hexarelin | Mechanistic inference, clinical experience reports | Directionally supported | Low | No direct head-to-head RCT comparing desensitization rates |
Head-to-head comparison: where each peptide wins and loses
| Parameter | Sermorelin | Hexarelin | Winner |
|---|---|---|---|
| Receptor target | GHRHR (pituitary somatotrophs) | GHSR-1a + CD36 | Depends on goal |
| GH pulse amplitude | Moderate, physiological range | Higher, can exceed physiological range | Hexarelin (raw GH output) |
| Cortisol and prolactin elevation | Minimal | Dose-dependent, documented | Sermorelin |
| Desensitization risk | Lower in clinical practice | Higher, documented within weeks of daily use | Sermorelin |
| Regulatory history | Former FDA approval (Geref, withdrawn 2008) | Never approved, research compound only | Sermorelin |
| Human evidence volume | Larger body of data including NDA package | Small trials, no NDA | Sermorelin |
| Hunger and appetite stimulation | Not a primary effect | Present via GHSR-1a (ghrelin-like effect) | Sermorelin (for those not wanting appetite increase) |
| Cardiac receptor activity | None documented | CD36 engagement (animal data) | Hexarelin (theoretical, not clinical) |
| Suitability for long protocols | Better supported | Requires cycling due to desensitization | Sermorelin |
| Cost (compounded, typical) | Generally lower | Generally higher | Sermorelin |
Which peptide has worse side effects?
Hexarelin produces a broader side-effect profile than sermorelin, and this is mechanistically predictable, not anecdotal.
Because GHSR-1a is expressed in corticotrophs and other pituitary cell types beyond somatotrophs, hexarelin stimulates ACTH and thus cortisol in a dose-dependent fashion. Studies in healthy adults (Ghigo et al., Journal of Clinical Endocrinology and Metabolism, 1994) demonstrated significant prolactin and cortisol elevation after hexarelin injection, with effect size correlated to dose. This effect is absent or negligible with sermorelin because GHRHR is somatotroph-selective.
Hexarelin also activates the appetite and hunger pathways through GHSR-1a, the same receptor that endogenous ghrelin activates. Users report increased hunger, particularly in the short post-injection window. This is not inherently dangerous but matters for body composition goals.
Sermorelin's most common side effects are injection site reactions (redness, swelling) and occasional flushing or headache. These are largely local and mild. Water retention can occur with any GH-stimulating agent.
Both peptides share the class-level concern that supraphysiological GH stimulation, when sustained, carries theoretical risk of insulin resistance, edema, and carpal tunnel-like symptoms, mirroring exogenous GH side effects. The risk is lower with physiological stimulation doses than with direct GH injection.
Does hexarelin really desensitize faster?
Yes, and the mechanism is well-characterized. GHSR-1a undergoes receptor internalization and downregulation with sustained or high-frequency agonist exposure. This is a property of GPCR biology broadly and has been documented specifically for GHRPs including hexarelin.
Human data from Ghigo and colleagues showed that repeated hexarelin administration leads to attenuation of GH response within a period of weeks of continuous use. The GHRHR that sermorelin targets is also subject to desensitization, but the clinical evidence for this occurring at standard dosing protocols is less robust, and most clinical experience with sermorelin is that GH responsiveness is maintained over months-long protocols when used at appropriate doses.
Practical implication: hexarelin protocols commonly incorporate cycling, for example 8 weeks on followed by a washout period of several weeks, specifically to allow receptor recovery. Sermorelin protocols are sometimes run for 3 to 6 months continuously under medical supervision without reported loss of response, though individual variation exists.
What do most comparison pages get wrong about hexarelin vs sermorelin?
Several high-traffic pages make claims that are either unfounded or misleadingly framed:
1. Equating both peptides as "GH secretagogues" with similar profiles. This implies they are interchangeable. They are not. Different receptor targets mean different systemic effects, different desensitization timelines, and different risk profiles. A patient with elevated cortisol or prolactin at baseline should not be treated as equivalent to one without.
2. Claiming hexarelin's CD36 cardiac effects are clinically proven. The CD36 cardioprotection data comes from animal and in vitro studies. There are no human RCTs demonstrating that hexarelin at research doses improves cardiac outcomes. Presenting this as a proven benefit is misleading.
3. Ignoring bioavailability limits. Both peptides must be injected. Oral administration results in peptide hydrolysis by gastrointestinal proteases before absorption, yielding negligible plasma concentrations of intact peptide. No reliable oral bioavailability data supports oral hexarelin or sermorelin use. Sublingual and intranasal routes have been investigated for some GHRPs but are not validated for these specific agents at the product quality levels available through compounders.
4. Omitting the purity and sourcing problem. Neither hexarelin nor sermorelin is available as a retail approved pharmaceutical in the United States. Compounded versions vary in purity. A legitimate compounded product from an accredited 503B outsourcing facility is meaningfully different from a peptide sourced from a research chemical supplier with no GMP oversight. Certificate of analysis from a third-party lab should confirm peptide identity, purity above 98%, and absence of endotoxins. Pages that discuss dosing without addressing sourcing quality are leaving out the most operationally critical variable.
5. Overstating the benefit of stacking. Combining a GHRP with a GHRH analogue is pharmacologically rational (they act on different receptors and their effects are additive to synergistic on GH pulse amplitude), but every site that recommends stacking hexarelin with sermorelin underemphasizes that you are also stacking the cortisol and prolactin burden of hexarelin with the total GH secretory load.
Why short half-life matters and what it means for dosing timing
Both hexarelin and sermorelin are peptides with plasma half-lives measured in minutes. Sermorelin pharmacokinetic studies report a half-life on the order of 10 to 20 minutes. Hexarelin's active plasma window is similarly short, with peak GH response occurring within roughly 15 to 30 minutes post-injection and returning toward baseline within 2 hours.
The short half-life is a consequence of peptide chemistry: these small peptides are subject to rapid cleavage by endogenous peptidases (dipeptidyl peptidase-4 in the case of sermorelin, and nonspecific serum proteases for both). This is not a storage stability issue but an in-vivo pharmacokinetic reality.
What this means practically:
- Injection timing matters. Administering these peptides immediately before sleep uses the naturally amplified nocturnal GH pulse, a strategy supported by the physiology of GHRH-driven GH secretion.
- Food in the stomach raises insulin and suppresses somatostatin release in a pattern that blunts GH response. Most protocols recommend fasting for at least 2 hours before injection. This is not a marketing rule; it reflects that elevated insulin and glucose directly suppress somatotroph GH release through somatostatin-mediated pathways.
- Reconstituted peptide in the vial does not face the same rapid degradation as injected peptide, but stability in solution is still finite (see operations section below).
How to read a COA and judge product quality for hexarelin and sermorelin
When evaluating a compounded or research-grade product, a certificate of analysis (COA) should confirm:
| Parameter | What to look for | Red flag |
|---|---|---|
| Peptide identity | HPLC or mass spectrometry confirmation of correct molecular weight (hexarelin: 887.1 Da; sermorelin: approximately 3358 Da) | COA shows only UV absorbance or no MS confirmation |
| Purity | Greater than or equal to 98% by HPLC | Purity below 95%, or purity stated without chromatogram |
| Endotoxin (LAL test) | Less than 1 EU/mg for injectable use | No endotoxin test listed; endotoxin untested research products are not appropriate for injection |
| Sterility | Sterility testing per USP 71 for 503B products | Research chemical suppliers rarely perform sterility testing; this is a material safety difference |
| Testing date | Within 12 months for lyophilized; recent for reconstituted | No date, or date over 2 years old |
What a degraded vial looks like: Lyophilized peptides are white to off-white powders. Yellowing, clumping, or moisture in a lyophilized vial suggests improper storage or cold-chain failure. Reconstituted peptide should be clear and colorless. Cloudiness, particulates, or pink to yellow discoloration in solution indicates degradation or contamination. Critically, loss of potency often occurs before visible changes. A vial that looks fine but was left at room temperature for several days may have substantially reduced activity.
Storage rule and why: Lyophilized vials at 2 to 8 degrees Celsius (standard refrigerator), away from light. Once reconstituted with bacteriostatic water (0.9% benzyl alcohol as preservative), store at 2 to 8 degrees Celsius and use within 28 to 30 days per standard compounding guidance. Do not freeze reconstituted peptide: freeze-thaw cycles promote peptide aggregation through disruption of hydrogen bonding networks in the peptide tertiary structure, reducing both potency and increasing the risk of particulate injection. Bacteriostatic water rather than sterile water is preferred for multi-dose vials because it inhibits microbial growth over the use period.
FAQ
What is the main difference between hexarelin and sermorelin?
Sermorelin is a GHRH analogue that binds the GHRH receptor and requires intact pituitary function. Hexarelin is a GHRP that binds the ghrelin receptor (GHSR-1a) and also has direct cardiac effects via CD36. They stimulate GH through different receptors and are not interchangeable.
Does hexarelin cause more desensitization than sermorelin?
Yes. Human studies show that continuous or high-frequency hexarelin dosing leads to measurable GH blunting within weeks, likely due to GHSR-1a downregulation. Sermorelin shows less desensitization in clinical use, making it more suitable for longer protocols without breaks.
Which peptide raises cortisol and prolactin more?
Hexarelin raises cortisol and prolactin more than sermorelin. Studies in healthy adults found hexarelin elevated prolactin and cortisol in a dose-dependent fashion. Sermorelin produces minimal cortisol or prolactin elevation at standard doses because GHRH receptors are not expressed on corticotrophs.
Is sermorelin FDA-approved?
Sermorelin acetate was previously FDA-approved as Geref for pediatric GH deficiency diagnosis and short stature treatment. That NDA was voluntarily withdrawn by the manufacturer in 2008. Compounded sermorelin is available through 503A and 503B pharmacies but is not itself an approved drug product.
What does hexarelin's CD36 receptor activity actually mean clinically?
Hexarelin binds CD36, a scavenger receptor expressed in cardiac tissue and macrophages. Animal studies show cardioprotective and anti-fibrotic effects independent of GH release. Human clinical data on this mechanism is very limited, so the cardiac claim is largely extrapolated from animal and in vitro work.
How do the half-lives of hexarelin and sermorelin compare?
Both peptides have short plasma half-lives measured in minutes. Sermorelin's half-life is reported at roughly 10 to 20 minutes in pharmacokinetic studies. Hexarelin has a similarly short half-life, with GH pulse peaking around 15 to 30 minutes post-injection and returning to baseline within 2 hours.
Can you stack hexarelin and sermorelin together?
Combining a GHRP like hexarelin with a GHRH analogue like sermorelin can produce additive or synergistic GH pulses, similar to the well-documented GHRP plus GHRH combination effect. However, stacking also stacks side effects including cortisol, prolactin, and hunger. Evidence for this specific combination in humans is limited to small studies.
What does a degraded hexarelin or sermorelin vial look like?
Both peptides in solution can degrade without visible changes. A compromised vial may show particulate matter, cloudiness, or discoloration, but loss of potency often precedes any visual sign. Reconstituted peptides stored improperly at room temperature will lose activity over days to weeks without looking different.
Which peptide is better studied in humans?
Sermorelin has a longer human research record including FDA-reviewed efficacy and safety data from its approved-drug era. Hexarelin has been studied in human trials but mostly in small, short-duration studies. Neither has large, long-term RCT data in the wellness or anti-aging context where they are most commonly used today.
How should reconstituted hexarelin and sermorelin be stored?
Lyophilized vials should be stored at 2 to 8 degrees Celsius and protected from light. Once reconstituted with bacteriostatic water, both peptides should be refrigerated and used within 28 to 30 days per standard compounding guidance. Freezing reconstituted peptide is not recommended as freeze-thaw cycles accelerate aggregation.
Does body fat percentage affect hexarelin response?
Yes. Higher body fat, particularly visceral fat, is associated with blunted GH secretion and reduced GHRP response. Hexarelin studies in obese subjects showed attenuated GH peaks compared to lean controls. Sermorelin response is similarly affected. This is a clinically important variable most protocols do not account for.
- Ghigo E, Arvat E, Rizzi G, et al. "Arginine enhances the growth hormone (GH)-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration." Journal of Endocrinological Investigation. 1994. (Hexarelin class pharmacology in human subjects.)
- Ghigo E, Arvat E, Goffi S, et al. "Effects of continuous infusion of hexarelin, a synthetic hexapeptide, on the GH response in normal aging." Journal of Clinical Endocrinology and Metabolism. 1994;79(2):380-384. (Human GH response and desensitization data.)
- Bowers CY. "Growth hormone-releasing peptide (GHRP)." Cellular and Molecular Life Sciences. 1998;54(12):1316-1329. (Review of GHRP receptor biology and mechanism.)
- Pandya N, DeMott-Friberg R, Bowers CY, Barkan AL, Jaffe CA. "Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation." Journal of Clinical Endocrinology and Metabolism. 1998;83(4):1186-1189. (Mechanism of GHRP-GHRH synergy.)
- Muccioli G, Broglio F, Valetto MR, et al. "Growth hormone-releasing peptides and the cardiovascular system." Annals of Endocrinology. 2000;61(1):27-31. (CD36 and hexarelin cardiac receptor evidence.)
- Bodart V, Bouchard JF, McNicoll N, et al. "Identification and characterization of a new growth hormone-releasing peptide receptor in the heart." Circulation Research. 1999;85(9):796-802. (CD36 receptor identification for hexarelin.)
- US FDA. Geref (sermorelin acetate) NDA historical data. Serono Laboratories, Inc. NDA voluntarily withdrawn 2008. (Regulatory history of sermorelin.)
- Walker RF. "Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?" Clinical Interventions in Aging. 2006;1(4):307-308. (Clinical review of sermorelin in aging adults.)
- Prakash A, Goa KL. "Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency." BioDrugs. 1999;12(2):139-157. (Pharmacokinetics including half-life data.)
- Arvat E, Gianotti L, Di Vito L, et al. "Modulation of growth hormone-releasing activity of hexarelin in man." Neuroendocrinology. 1995;61(1):51-56. (Desensitization and cortisol/prolactin elevation data in humans.)